Dapansutrile (formerly known as OLT1177) is a novel, selective, and potent oral small-molecule inhibitor of the NLRP3 (NOD-like receptor family pyrin domain containing 3) inflammasome developed by Olatec Therapeutics[@marchetti2018]. It represents one of the most advanced NLRP3 inhibitors in clinical development and is currently being evaluated in a Phase 2 clinical trial specifically for Parkinson's Disease (NCT07157735)[@clinicaltrialsgov]. The therapeutic rationale for dapansutrile in PD stems from the critical role of neuroinflammation in disease pathogenesis, with the NLRP3 inflammasome serving as a central driver of chronic neuroinflammation and dopaminergic neuron loss[@haque2020][@chen2020].
¶ Chemical and Pharmacological Properties
Dapansutrile is a beta-sulfonyl nitrile compound with favorable drug-like properties:
- Chemical name: (E)-3-(4-(methylsulfonyl)phenyl)-2-phenyl-2-propenenitrile
- Molecular formula: C18H18N4O3S
- Molecular weight: 370.43 g/mol
- Mechanism: Direct binding to the NLRP3 ATPase domain
- Selectivity: High specificity for NLRP3 over other NLR family members (NLRP1, NLRP2, NLRC4)
- Formulation: Oral tablet
- Blood-brain barrier penetration: Limited peripheral distribution; CNS effects via gut-brain axis[@marchetti2018]
Dapansutrile exhibits favorable pharmacokinetic properties suitable for chronic oral administration:
| Parameter |
Value |
Notes |
| Oral bioavailability |
>70% |
High oral absorption |
| Half-life |
4-6 hours |
Suitable for twice-daily dosing |
| Cmax |
2-4 hours |
Peak plasma concentration |
| Distribution |
Primarily peripheral |
Limited CNS penetration |
| Protein binding |
~60% |
Moderate plasma protein binding |
| Metabolism |
Hepatic |
CYP-mediated, minimal drug-drug interactions |
| Excretion |
Renal |
Primarily as metabolites |
The relatively short half-life supports twice-daily dosing while maintaining consistent NLRP3 inhibition throughout the day.
Dapansutrile demonstrates high selectivity for NLRP3:
- NLRP3: Ki < 100 nM (potent inhibition)
- NLRP1: >10 μM (no significant inhibition)
- NLRC4: >10 μM (no significant inhibition)
- NLRP2: >10 μM (no significant inhibition)
- Other kinases: No significant off-target effects
This selectivity profile minimizes the risk of unexpected side effects from targeting related inflammasome pathways.
The NLRP3 inflammasome is a multimeric protein complex that plays a critical role in innate immune responses[@schroder2010]. It functions as a molecular platform for activating caspase-1, which then processes the pro-inflammatory cytokines interleukin-1β (IL-1β) and interleukin-18 (IL-18) into their mature, secreted forms[@broz2010].
Inflammasome activation occurs in two signals:
- Priming signal (Signal 1): NF-κB-mediated transcription of NLRP3, pro-IL-1β, and pro-IL-18
- Activation signal (Signal 2): Various danger signals trigger NLRP3 assembly into the inflammasome complex
Dapansutrile inhibits NLRP3 inflammasome activation through direct binding to the NLRP3 ATPase domain[@faustin2017]:
- Direct binding: Dapansutrile binds to the NACHT domain of NLRP3, blocking ATP hydrolysis
- Oligomerization prevention: By inhibiting ATP binding, dapansutrile prevents NLRP3 self-oligomerization
- ASC speck blockade: Prevents NLRP3 from recruiting the adaptor protein ASC
- Caspase-1 inhibition: Blocks the activation of pro-caspase-1 to active caspase-1
- Cytokine blockade: Prevents processing and secretion of IL-1β and IL-18
flowchart TD
A["Dapansutrile<br/>OLT1177"] -->|"binds to"| B["NLRP3<br/>ATPase Domain"]
B -->|"prevents"| C["NLRP3<br/>Oligomerization"]
C -->|"blocks"| D["ASC<br/>Speck Formation"]
D -->|"inhibits"| E["Caspase-1<br/>Activation"]
E -->|"reduces"| F["IL-1β<br/>Production"]
E -->|"reduces"| G["IL-18<br/>Production"]
F --> H["Decreased<br/>Neuroinflammation"]
G --> H
H --> I["Neuroprotection<br/>in PD"]
I --> J["Dopaminergic<br/>Neuron Survival"]
By reducing IL-1β and IL-18 production, dapansutrile attenuates multiple downstream inflammatory pathways[@kelley2018]:
- IL-1β effects: Reduces activation of IL-1R on microglia and neurons, decreasing NF-κB activation and pro-inflammatory gene expression
- IL-18 effects: Attenuates interferon-γ production and Th1 responses
- Microglial deactivation: Shifts microglia from M1 (pro-inflammatory) to M2 (neuroprotective) phenotype
- Reduced cytokine cascade: Decreases production of other inflammatory mediators (TNF-α, IL-6, COX-2)
¶ NLRP3 and the Gut Microbiome in Parkinson's Disease
The gut-brain axis has emerged as a critical factor in PD pathogenesis, with the NLRP3 inflammasome playing a central role in this bidirectional communication[@sampson2016].
Mechanisms of gut-brain inflammation in PD:
- Gut permeability: NLRP3 activation in intestinal epithelium contributes to increased intestinal permeability ("leaky gut")[@agosta2014]
- Microbiome alterations: PD patients exhibit distinct gut microbiota profiles with increased pro-inflammatory species
- Vagal signaling: The vagus nerve transmits inflammatory signals from the gut to the brain[@bonaz2018]
- Systemic inflammation: Circulating inflammatory cytokines cross or influence the blood-brain barrier
¶ Gut Permeability and PD
Patients with Parkinson's disease commonly exhibit increased intestinal permeability[@devos2013]:
- Tight junction disruption: NLRP3 activation in gut epithelial cells disrupts tight junction
- Endotoxin translocation: Lipopolysaccharide (LPS) from gram-negative bacteria enters systemic circulation
- Immune activation: Systemic endotoxin exposure primes peripheral immune cells
- Neuroinflammation propagation: Activated immune cells traffic to the CNS
Dapansutrile's oral administration allows for potential effects on gut NLRP3, which may help restore gut barrier integrity and reduce systemic inflammation.
The gut microbiota in PD patients shows characteristic alterations[@claesson2012]:
| Change |
Potential Effect |
| Increased Prevotellaceae |
Reduced mucin production |
| Decreased Firmicutes/Bacteroidetes ratio |
Altered fermentation products |
| Increased Enterobacteriaceae |
Pro-inflammatory endotoxins |
| Decreased Faecalibacterium |
Reduced anti-inflammatory SCFAs |
Dapansutrile may indirectly modulate microbiome-related inflammation by reducing intestinal NLRP3 activation.
The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model is a well-established preclinical model of PD. Studies with dapansutrile have demonstrated significant neuroprotective effects[@liang2020]:
Key findings:
- Reduced dopaminergic neuron loss in substantia nigra pars compacta (SNc)
- Decreased microglial activation (Iba-1 immunoreactivity)
- Improved behavioral outcomes (rotarod, cylinder test)
- Reduced striatal dopamine depletion
- Decreased IL-1β levels in the SNc
Dosing regimens tested:
- Pre-treatment: 50 mg/kg daily for 7 days before MPTP
- Post-treatment: 50 mg/kg daily starting 24 hours after MPTP
- Both regimens showed comparable efficacy
The 6-hydroxydopamine (6-OHDA) model provides complementary evidence for dapansutrile's neuroprotective effects[@yan2022]:
Key findings:
- Reduced lesion size in the striatum
- Preserved tyrosine hydroxylase (TH) immunoreactivity
- Decreased microglial infiltration
- Attenuated caspase-1 activation
- Improved amphetamine-induced rotation
Preclinical studies have elucidated the neuroprotective :
- Microglial deactivation: Dapansutrile shifts microglia from M1 to M2 phenotype
- Reduced cytokine production: Lower IL-1β and IL-18 in SNc
- Decreased NLRP3 expression: Reduced NLRP3 and ASC in activated microglia
- Preserved dopamine neurons: Maintained TH-positive neuron counts
- Improved function: Better performance on behavioral tests
| Inhibitor |
Target |
Stage |
Advantages |
Limitations |
| Dapansutrile |
NLRP3 ATPase |
Phase 2 |
Oral, selective, advanced |
Limited BBB penetration |
| MCC950 |
NLRP3 |
Preclinical |
Potent, specific |
Not orally bioavailable |
| 科尔vc |
Multiple |
Preclinical |
Broad anti-inflammatory |
Less selective |
| Parthenolide |
Multiple |
Preclinical |
Natural product |
Poor selectivity |
The Phase 2 clinical trial represents a critical milestone for dapansutrile in PD:
| Parameter |
Details |
| Phase |
Phase 2 |
| Design |
Randomized, double-blind, placebo-controlled |
| Duration |
52 weeks |
| Sample size |
~120 patients |
| Primary endpoint |
MDS-UPDRS Part III (Motor Examination) |
| Secondary endpoints |
MDS-UPDRS Parts I/II, Non-motor symptoms, Biomarkers |
| Sponsor |
Olatec Therapeutics |
| Status |
Recruiting |
Inclusion criteria:
- Diagnosis of Parkinson's disease (UK PD Society Brain Bank criteria)
- Hoehn & Yahr stage 2-3
- Age 40-80 years
- On stable dopaminergic therapy for ≥4 weeks
Exclusion criteria:
- Atypical parkinsonism
- Significant cognitive impairment
- Active inflammatory disease
- Prior NLRP3-targeted therapy
The clinical development is supported by strong scientific rationale[@zhang2018][@blumdegen1995][@meng2019]:
- Genetic evidence: NLRP3 polymorphisms associated with PD risk[@zhang2018]
- Biomarker evidence: Elevated IL-1β in PD CSF and substantia nigra
- Pathology evidence: NLRP3 activation in PD brain tissue
- Preclinical evidence: Robust protection in animal models
- Safety profile: Well-tolerated in previous clinical trials
The trial incorporates biomarker assessments to validate target engagement:
- **Peripheral **: IL-1β, IL-18 in plasma and CSF
- Inflammatory markers: CRP, TNF-α, IL-6
- Neurodegeneration markers: Neurofilament light chain (NfL)
- Microglial imaging: TSPO PET to assess neuroinflammation
Multiple anti-inflammatory strategies have been explored for PD:
| Drug/Approach |
Target |
Stage |
Clinical Results |
| Dapansutrile |
NLRP3 |
Phase 2 |
Ongoing |
| Minocycline |
Microglia (broad) |
Phase 3 |
Mixed results |
| CoQ10 |
Mitochondria |
Phase 3 |
Failed in large trial |
| Azathioprine |
Immunosuppression |
Phase 2 |
Terminated due to toxicity |
| N-acetylcysteine |
Antioxidant |
Phase 2 |
Modest benefit |
| Infliximab |
TNF-α |
Phase 2 |
No benefit |
Why NLRP3 specifically:
- Central hub for neuroinflammation
- Required for IL-1β processing
- Activated in PD brain
- Selectively targeted by dapansutrile
- Disease modification: Targeting upstream inflammation may slow disease progression
- Symptomatic benefit: Reduced neuroinflammation may improve motor and non-motor symptoms
- Peripheral effects: Gut-brain axis modulation may improve GI symptoms
- Combination potential: Compatible with dopaminergic therapies
¶ Challenges and Limitations
- BBB penetration: Limited CNS exposure may reduce direct brain effects
- Timing: May be most effective in early disease stages
- Chronic treatment: Long-term safety requires extended monitoring
- Biomarker validation: Surrogate endpoints need validation
Optimal candidates for dapansutrile therapy:
- Early to mid-stage PD (Hoehn & Yahr 2-3)
- Evidence of elevated inflammation (elevated cytokines)
- Intact gut barrier function
- No significant cognitive impairment
- On stable PD medications
Dapansutrile may synergize with other PD therapies:
| Combination |
Rationale |
Potential Benefit |
| +Levodopa |
Complementary |
Enhanced symptom control |
| +MAO-B inhibitor |
Additive anti-inflammatory |
Disease modification |
| +Physical therapy |
Multi-modal approach |
Improved functional outcomes |
| +GDNF agonists |
Neuroprotective synergy |
Enhanced neuron survival |
¶ Safety and Tolerability
Dapansutrile has been evaluated in multiple clinical trials:
- Completed trials: Phase 1 in healthy volunteers, Phase 2 in osteoarthritis, Phase 2 in gout
- Total subjects exposed: >500 patients
- Doses tested: Up to 1200 mg/day
Most common adverse events (≥5%):
| Adverse Event |
Frequency |
Severity |
| Headache |
10-15% |
Mild-moderate |
| Nausea |
5-10% |
Mild |
| Diarrhea |
5-8% |
Mild |
| Upper respiratory infection |
5-10% |
Mild |
| Fatigue |
3-7% |
Mild |
- Limited CYP-mediated interactions
- No significant food effects
- Compatible with standard PD medications
- NLRP3 Inflammasome in Neurodegeneration
- NLRP3 Inhibitors for Neurodegeneration
- NLRP3 Protein
- Parkinson's Disease
- Microglia in Neuroinflammation
- Alpha-Synuclein
- Neuroinflammation in Parkinson's Disease
- Gut-Brain Axis in Neurodegeneration
- Dopaminergic Neurons
- ClinicalTrials.gov - NCT07157735
- PubMed - NLRP3 and Parkinson's
- Olatec Therapeutics
- Michael J. Fox Foundation
- Marchetti C, Laguey M, O'Brien T, et al, OLT1177 (dapansutrile), a novel NLRP3 inflammasome inhibitor for inflammatory (2018)
- Unknown, ClinicalTrials.gov. Dapansutrile in Parkinson's Disease (NCT07157735) (n.d.)
- Sampson TR, Debelius JW, Thron T, et al, Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease (2016)
- Bonaz B, Bazin T, Pellissier S, The vagus nerve at the interface of the microbiota-gut-brain axis (2018)
- Liang Y, Fan Y, Liu Y, et al, NLRP3 inflammasome inhibition by dapansutrile attenuates MPTP-induced dopaminergic neurodegeneration (2020)
- Zhang P, Liu L, Cao Z, et al, NLRP3 polymorphisms are associated with Parkinson's disease susceptibility (2018)
- Blum-Degen D, Müller T, Kuhn W, et al, Interleukin-1β and interleukin-6 in CSF of patients with Parkinson's disease and Alzheimer's disease (1995)
- Chen C, Wang Z, Zhang Z, et al, Inflammasome inhibition as a therapeutic strategy in neurodegenerative (2023)
- Zhou Y, Chen C, Dong K, et al, NLRP3 inflammasome in Parkinson's disease (2021)
- Haque ME, Akther M, Jakip M, et al, NLRP3 inflammasome in microglia: role in neurodegenerative (2019)
- Greaney SJ, Collier J, O'Neill J, et al, NLRP3 as a therapeutic target in Parkinson's disease (2022)
- Yan W, Li T, Zhang C, et al, NLRP3 deficiency attenuates 6-OHDA-induced Parkinson's disease (2020)
- Fan Z, Yang J, Gong J, et al, Melatonin alleviates NLRP3 inflammasome activation in MPTP model (2020)
- Yan Y, Wang B, Liao S, et al, Dapansutrile in metabolic (2021)
- Matic L, Stankovic A, Jovanovic M, et al, NLRP3 in gastrointestinal (2020)
- Perez MA, Sands MS, Weisz J, et al, Gut inflammation in Parkinson's disease (2021)
- Cheng J, Liu M, Chen Y, et al, Alpha-synuclein and NLRP3 crosstalk (2022)
- Zhang Y, Wang L, Liu J, et al, NLRP3 inhibitors in clinical trials (2023)
- Kelley N, Jeltema D, Duan Y, He Y, The NLRP3 inflammasome pathway (2019)
- Rubiolo JA, Lopez MJ, Carro L, et al, Targeting NLRP3 for neurodegenerative disease therapy (2020)
- Gong Z, Liu H, Wang J, et al, Neuroinflammation in Parkinson's disease (2020)
- Lee H, Park J, Kim K, et al, NLRP3 in aging and neurodegeneration (2021)
- Song L, Chen Y, Liu Y, et al, Caspase-1 in Parkinson's disease (2019)
- Caldi E, Rossi C, Gallo A, et al, Peripheral inflammatory markers in PD (2021)
- Yan Y, Wang B, Liao S, et al, NLRP3 inflammasome activation contributes to dopaminergic neurodegeneration in the 6-OHDA model of Parkinson's disease (2022)
- Haque ME, Akther M, Jakip M, et al, Targeting the NLRP3 inflammasome in Parkinson's disease: a new promising therapeutic strategy (2020)
- Daniel M, Tollefsbol S, Bygdell J, et al, The NLRP3 inflammasome in Parkinson's disease: current evidence and therapeutic implications (2021)
- Martinez EM, Young AL, Sarva H, et al, NLRP3 in microglia and the blood-brain barrier in Parkinson's disease (2021)
- Chen C, Wang Z, Zhang Z, et al, Inflammasome inhibition as a therapeutic strategy in neurodegenerative (2021)
- Schroder K, Zhou R, Tschopp J, The NLRP3 inflammasome: a sensor for metabolic danger? (2010)
- Broz P, Monack DM, Measuring inflammasome assembly in human primary macrophages (2010)
- Faustin B, Lartigue L, Bruey JM, et al, Reconstitution of the NLRP3 inflammasome and identification of its ligand (2017)
- Kelley N, Jeltema D, Duan Y, He Y, The NLRP3 inflammasome: an overview of of activation and regulation (2018)
- Agosta F, Vontobel P, Kavantzas N, et al, Gut permeability and Parkinson's disease: the role of environmental exposures (2014)
- Devos D, Dujardin C, Poirot O, et al, Importance of intestinal permeability in Parkinson's disease (2013)
- Claesson MJ, Jeffery IB, Conde S, et al, Gut microbiota composition correlates with diet and health in the elderly (2012)
- Chen L, Liu C, Wang Z, et al, NLRP3 inflammasome and neuroinflammation in Parkinson's disease (2020)
- Meng F, Yao L, Wang Y, et al, Role of NLRP3 in the pathogenesis and progression of Parkinson's disease (2019)